Effect of inhibition of angiotensin-converting enzyme and/or neutral endopeptidase on neuropathy in high-fat-fed C57Bl/6J Mice

Journal of Obesity

Volumn 2012, Issue , 2012, Pages

  Coppey, Lawrence ^a,b   Lu, Bao ^c   Gerard, Craig ^c   Yorek, Mark A ^a,b  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANDOXATRIL; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; ILEPATRIL; MEMBRANE METALLOENDOPEPTIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GLUCOSE TOLERANCE; GLUCOSE UTILIZATION; LIPID DIET; MOUSE; NERVE FIBER; NERVE FUNCTION; NEUROPATHY; NOCICEPTION; NONHUMAN; OBESITY;

EID: 84877293097     PISSN: 20900708     EISSN: 20900716     Source Type: Journal    
DOI: 10.1155/2012/326806     Document Type: Article

References (42)

1. Davidson E. P., Coppey L. J., Lu B., Arballo V., Calcutt N. A., Gerard C., Yorek M. A., The roles of streptozotocin neurotoxicity and neutral endopeptidase in murine experimental diabetic neuropathy. Experimental Diabetes Research 2009 2009 2-s2.0-77951239664 431980
2. Coppey L. J., Davidson E. P., Lu B., Gerard C., Yorek M. A., Vasopeptidase inhibitor ilepatril (AVE7688) prevents obesity- and diabetes-induced neuropathy in C57Bl/6J mice. Neuropharmacology 2011 60 2-3 259 266 2-s2.0-78650825118 10.1016/j.neuropharm.2010.09.008
3. Weber M., Emerging treatments for hypertension: potential role for vasopeptidase inhibition. American Journal of Hypertension 1999 12 11, part 2 139S 147S 2-s2.0-0032712735
4. Sharma A. M., Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 2004 44 1 12 19 2-s2.0-3042528755 10.1161/01.HYP.0000132568.71409.a2 (Pubitemid 38823478)
5. Vatter H., Schilling L., Schmiedek P., Ehrenreich H., Evidence for functional endothelin-converting enzyme activity in isolated rat basilar artery: effect of inhibitors. Journal of Cardiovascular Pharmacology 1998 31 1 S64 S67 2-s2.0-0031639676 (Pubitemid 128709871)
6. Gonzalez W., Soleilhac J. M., Fournié-Zaluski M. C., Roques B. P., Michel J. B., Characterization of neutral endopeptidase in vascular cells, modulation of vasoactive peptide levels. European Journal of Pharmacology 1998 345 3 323 331 2-s2.0-0032568304 10.1016/S0014-2999(98)00038-7 (Pubitemid 28179575)
7. Edwards R. M., Pullen M., Nambi P., Distribution of neutral endopeptidase activity along the rat and rabbit nephron. Pharmacology 1999 59 1 45 50 2-s2.0-0033044952 10.1159/000028304 (Pubitemid 29261517)
8. Ebihara F., Seno Di Marco G., Juliano M. A., Casarini D. E., Neutral endopeptidase expression in mesangial cells. Journal of the Renin-Angiotensin- Aldosterone System 2003 4 4 228 233 2-s2.0-0346258346 (Pubitemid 38008174)
9. Muangman P., Spenny M. L., Tamura R. N., Gibran N. S., Fatty acids and glucose increase neutral endopeptidase activity in human microvascular endothelial cells. Shock 2003 19 6 508 512 2-s2.0-0347325158
10. Matsas R., Kenny A. J., Turner A. J., An immunohistochemical study of endopeptidase-24.11 ("enkephalinase") in the pig nervous system. Neuroscience 1986 18 4 991 1012 2-s2.0-0022877471 (Pubitemid 16074939)
11. Kioussi C., Mamalaki A., Jessen K., Mirsky R., Hersh L. B., Matsas R., Expression of endopeptidase-24.11 (common acute lymphoblastic leukaemia antigen CD10) in the sciatic nerve of the adult rat after lesion and during regeneration. European Journal of Neuroscience 1995 7 5 951 961 2-s2.0-0029050033 10.1111/j.1460-9568.1995.tb01083.x
12. Pu Q., Schiffrin E. L., Effect of ACE/NEP inhibition on cardiac and vascular collagen in stroke-prone spontaneously hypertensive rats. American Journal of Hypertension 2001 14 10 1067 1072 2-s2.0-0034774067 10.1016/S0895-7061(01)02157-4 (Pubitemid 32978081)
13. Floras J. S., Vasopeptidase inhibition: a novel approach to cardiovascular therapy. Canadian Journal of Cardiology 2002 18 2 177 182 2-s2.0-0036116829 (Pubitemid 34406620)
14. Davidson E. P., Kleinschmidt T. L., Oltman C. L., Lund D. D., Yorek M. A., Treatment of streptozotocin-induced diabetic rats with AVE7688, a vasopeptidase inhibitor: effect on vascular and neural disease. Diabetes 2007 56 2 355 362 2-s2.0-33847027944 10.2337/db06-1180
15. Oltman C. L., Davidson E. P., Coppey L. J., Kleinschmidt T. L., Yorek M. A., Treatment of Zucker diabetic fatty rats with AVE7688 improves vascular and neural dysfunction. Diabetes, Obesity and Metabolism 2009 11 3 223 233 2-s2.0-59349098165 10.1111/j.1463-1326.2008.00924.x
16. Davidson E. P., Coppey L. J., Kleinschmidt T. L., Oltman C. L., Yorek M. A., Vascular and neural dysfunctions in obese Zucker rats: effect of AVE7688. Experimental Diabetes Research 2009 2009 2-s2.0-68849113240 912327
17. Lu B., Gerard N. P., Kolakowski L. F. Jr., Bozza M., Zurakowski D., Finco O., Carroll M. C., Gerard C., Neutral endopeptidase modulation of septic shock. Journal of Experimental Medicine 1995 181 6 2271 2275 2-s2.0-0029040138 10.1084/jem.181.6.2271
18. Ayoub S., Melzig M. F., Induction of neutral endopeptidase (NEP) activity of SK-N-SH cells by natural compounds from green tea. Journal of Pharmacy and Pharmacology 2006 58 4 495 501 2-s2.0-33645562327 10.1211/jpp.58.4.0009
19. Davidson E. P., Coppey L. J., Dake B., Yorek M. A., Effect of treatment of sprague dawley rats with AVE7688, enalapril or candoxatril on diet induced obesity. Journal of Obesity 2011 2011 686952
20. Beiswenger K. K., Calcutt N. A., Mizisin A. P., Epidermal nerve fiber quantification in the assessment of diabetic neuropathy. Acta Histochemistry 2008 110 5 351 362
21. Santos E. L., de Picoli Souza K., Guimarães P. B., Reis F. C. G., Silva S. M. A., Costa-Neto C. M., Luz J., Pesquero J. B., Effect of angiotensin converting enzyme inhibitor enalapril on body weight and composition in young rats. International Immunopharmacology 2008 8 2 247 253 2-s2.0-37549006769 10.1016/j.intimp.2007.07.021
22. Weisinger R. S., Stanley T. K., Begg D. P., Weisinger H. S., Spark K. J., Jois M., Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet. Physiology and Behavior 2009 98 1-2 192 197 2-s2.0-67649486849 10.1016/j.physbeh.2009.05.009
23. Santos E. L., de Picoli Souza K., da Silva E. D., Batista E. C., Martins P. J. F., D'Almeida V., Pesquero J. B., Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats. Biochemical Pharmacology 2009 78 8 951 958 2-s2.0-69549095825 10.1016/j.bcp.2009.06.018
24. Araki K., Masaki T., Katsuragi I., Tanaka K., Kakuma T., Yoshimatsu H., Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 2006 48 1 51 57 2-s2.0-33745982069 10.1161/01.HYP.0000225402.69580.1d (Pubitemid 44297524)
25. Jayasooriya A. P., Mathai M. L., Walker L. L., Begg D. P., Denton D. A., Cameron-Smith D., Egan G. F., McKinley M. J., Rodger P. D., Sinclair A. J., Wark J. D., Weisinger H. S., Jois M., Weisinger R. S., Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proceedings of the National Academy of Sciences of the United States of America 2008 105 18 6531 6536 2-s2.0-44349141660 10.1073/pnas.0802690105 (Pubitemid 351754541)
26. Kouyama R., Suganami T., Nishida J., Tanaka M., Toyoda T., Kiso M., Chiwata T., Miyamoto Y., Yoshimasa Y., Fukamizu A., Horiuchi M., Hirata Y., Ogawa Y., Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 2005 146 8 3481 3489 2-s2.0-23044505229 10.1210/en.2005-0003 (Pubitemid 41065022)
27. Nawano M., Anai M., Funaki M., Kobayashi H., Kanda A., Fukushima Y., Inukai K., Ogihara T., Sakoda H., Onishi Y., Kikuchi M., Yazaki Y., Oka Y., Asano T., Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat. Metabolism 1999 48 10 1248 1255 2-s2.0-13044280784 10.1016/S0026-0495(99)90263-9 (Pubitemid 29496071)
28. Henriksen E. J., Jacob S., Augustin H. J., Dietze G. J., Glucose transport activity in insulin-resistant rat muscle: effects of angiotensin-converting enzyme inhibitors and bradykinin antagonism. Diabetes 1996 45 supplement 1 S125 S128 2-s2.0-0030032963 (Pubitemid 26012002)
29. Henriksen E. J., Jacob S., Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism 1995 44 2 267 272 2-s2.0-0028931911
30. Sugimoto K., Kazdová L., Qi N. R., Hyakukoku M., Křen V., Šimáková M., Zídek V., Kurtz T. W., Pravenec M., Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor- γ dependent pathway. Journal of Hypertension 2008 26 6 1209 1215 2-s2.0-43449087025 10.1097/HJH. 0b013e3282f9b58a (Pubitemid 351670512)
31. Russell J. C., Kelly S. E., Schäfer S., Vasopeptidase inhibition improves insulin sensitivity and endothelial function in the JCR:LA-cp rat. Journal of Cardiovascular Pharmacology 2004 44 2 258 265 2-s2.0-3242790173 10.1097/00005344-200408000-00016 (Pubitemid 38982170)
32. Arbin V., Claperon N., Fournié-Zaluski M. C., Roques B. P., Peyroux J., Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat. British Journal of Pharmacology 2001 133 4 495 502 2-s2.0-0034957092 (Pubitemid 32591915)
33. Wang C. H., Leung N., Lapointe N., Szeto L., Uffelman K. D., Giacca A., Rouleau J. L., Lewis G. F., Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker. Circulation 2003 107 14 1923 1929 2-s2.0-0037446690 10.1161/01.CIR.0000062646.09566.CC (Pubitemid 36444136)
34. Wong V., Szeto L., Uffelman K., Fantus I. G., Lewis G. F., Enhancement of muscle glucose uptake by the vasopeptidase inhibitor, omapatrilat, is independent of insulin signaling and the AMP kinase pathway. Journal of Endocrinology 2006 190 2 441 450 2-s2.0-33747874336 10.1677/joe.1.06396 (Pubitemid 44288380)
35. Miyashita K., Itoh H., Tsujimoto H., Tamura N., Fukunaga Y., Sone M., Yamahara K., Taura D., Inuzuka M., Sonoyama T., Nakao K., Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes 2009 58 12 2880 2892 2-s2.0-73249127018 10.2337/db09-0393
36. Yorek M. A., The potential role of angiotensin converting enzyme and vasopeptidase inhibitors in the treatment of diabetic neuropathy. Current Drug Targets 2008 9 1 77 84 2-s2.0-38849159059 10.2174/138945008783431736 (Pubitemid 351201682)
37. Yang H. Y. T., Erdös E. G., Levin Y., A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochimica et Biophysica Acta 1970 214 2 374 376 2-s2.0-0014957830
38. Henriksen E. J., Jacob S., Kinnick T. R., Youngblood E. B., Schmit M. B., Dietze G. J., ACE inhibition and glucose transport in insulin-resistant muscle: roles of bradykinin and nitric oxide. American Journal of Physiology 1999 277 1 R332 R336 2-s2.0-0032767731 (Pubitemid 29356810)
39. Coppey L. J., Davidson E. P., Rinehart T. W., Gellett J. S., Oltman C. L., Lund D. D., Yorek M. A., ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetes 2006 55 2 341 348 2-s2.0-33644785987 10.2337/diabetes.55.02.06.db05- 0885 (Pubitemid 43343262)
40. Oltman C. L., Davidson E. P., Coppey L. J., Kleinschmidt T. L., Dake B., Yorek M. A., Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats. European Journal of Pharmacology 2011 650 2-3 556 562 2-s2.0-78651113487 10.1016/j.ejphar.2010.10.047
41. Engeli S., Role of the renin-angiotensin-aldosterone system in the metabolic syndrome. Contributions to Nephrology 2006 151 122 134 2-s2.0-33748047823 10.1159/000095324 (Pubitemid 44298227)
42. Standeven K. F., Hess K., Carter A. M., Rice G. I., Cordell P. A., Balmforth A. J., Lu B., Scott D. J., Turner A. J., Hooper N. M., Grant P. J., Neprilysin, obesity and the metabolic syndrome. International Journal of Obesity 2011 35 1031 1040 2-s2.0-77958609543 10.1038/ijo.2010.227